If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro™ (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Has Mounjaro™ (tirzepatide) been studied in patients with polycystic ovary syndrome (PCOS)?
Eli Lilly and Company has not sponsored any clinical studies to evaluate the safety or efficacy of tirzepatide in patients with PCOS.
See important safety information, including boxed warning, in the attached prescribing information.
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) for once-weekly, subcutaneous administration.1
Patients With Polycystic Ovary Syndrome
Eli Lilly and Company has not sponsored a study to evaluate the safety and efficacy of tirzepatide in patients with polycystic ovary syndrome (PCOS). However, patients with polycystic ovaries were not excluded from the phase 3 clinical development program.2
Enclosed Prescribing Information
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: August 08, 2022